PIAS Proteins and Its Monoclonal Antibody as Diagnostics and Therapeutics for Immunological Disorders and Cancer
Both the PIAS proteins and the PIAS1 monoclonal antibody may be developed as therapeutics and diagnostics for cancers and immune disorders that involve the signaling through pathways regulated by PIAS.
Researchers at the University of California, Los Angeles have identified a family of proteins named protein inhibitor of activated STAT (PIAS). The PIAS family regulates the activity of many transcription factors, including STATs, NF- κB, and SMADs. The PIAS family consists of PIAS1, PIAS3, PIASx (also known as PIAS2), and PIASy (also known as PIAS4). Researchers have also developed a PIAS1 monoclonal antibody. In addition to the already mentioned transcription proteins, researchers have also shown PIAS to regulate other gene-activation pathways in the immune system and in cancer.
Patent Number: US7265202B1
Application Number: US2000573651A
Inventor: Shuai, Ke | Chung, Chan | Liao, Jiayu | Liu, Bin | Rao, Xiaoping
Priority Date: 28 Nov 1997
Priority Number: US7265202B1
Application Date: 13 Nov 2000
Publication Date: 4 Sep 2007
IPC Current: C07K000100
US Class: 530350 | 4350071 | 4350691 | 530300
Assignee Applicant: The Regents of the University of California
Title: PIAS molecules that recognize and bind STAT proteins and uses thereof
Usefulness: PIAS molecules that recognize and bind STAT proteins and uses thereof
Summary: PIAS (I) is useful for blocking the DNA-binding activity of a STAT protein by contacting a PIAS molecule with STAT (claimed). It is useful for detection and treatment of diseases associated with STAT mediated cellular responses. Nuclear extracts from HepG2 cells were prepared and analyzed in mobility gel shift assays, with high-affinity STAT3-binding site as the probe. Treatment with IL6 induced the binding of three distinct gel shift complexes corresponding to a STAT3-STAT3 homodimer, a STAT3-STAT1 heterodimer, and a STAT1-STAT1 homodimer. A recombinant fusion of GST with PIAS was prepared and added to IL6-treated HepG2 nuclear extracts. It completely inhibited the DNA-binding activity of the STAT3-STAT3 homodimer and STAT3-STAT1 heterodimer, but not the STAT1-STAT1 homodimer.
Novelty: New Protein Inhibitor of Activated STAT used for, e.g. treatment of diseases associated with STAT mediated cellular responses
Biomedical
Medical Composition
7265202
Background Signal transducer and activator of transcription proteins (STATs), nuclear factor-κB (NF- κB), and SMA (small body size)- and MAD (mothers against decapentapegic)-related proteins (SMADs) are three key families of transcription factors that are widely used downstream of cytokine-mediated signaling to regulate gene expression. The activity of STATs, NF- κB, and SMADs is tightly regulated at several levels, and inappropriate regulation can result in diseases in humans, including cancers and immune disorders. Tech ID/UC Case 20089/1998-541-0 Related Cases 1998-541-0
USA
